Patent battles threaten U.S. healthcare innovation and drug shortages worsen

The U.S. patent system is under pressure from legislative and judicial challenges. These hurdles threaten to slow down innovation in critical fields like healthcare. Sherry Knowles, a prominent figure in intellectual property, has highlighted the system’s vital role in advancing life-saving treatments. Sherry Knowles, founder of Knowles Intellectual Property Strategies, once served as Chief Patent Counsel for GlaxoSmithKline. As a cancer survivor, she credits drugs like Adriamycin and Herceptin with saving her life. She argues that patents are deeply personal, representing the work of small teams striving to transform lives through science.

The current system faces obstacles that could stifle progress. The Patent Eligibility Restoration Act (PERA) seeks to correct judicial rulings that have been deemed unconstitutional and harmful to pharmaceutical innovation. Knowles has urged lawmakers to consider personal stories, hoping to sway debates towards stronger patent protections.

The FDA reports that 89 generic drugs are in critically low supply, including 24 antibiotics and 21 oncology treatments. Generic versions of drugs are not always identical to brand-name medications. For some patients, they may not provide the same effectiveness. A strong patent system is seen as crucial for the U.S. to remain a leader in global healthcare innovation. Without it, the development of new treatments could face delays. The ongoing shortages of essential drugs underscore the need for a system that supports both innovation and access.